Abstract
Covering the Cover
Highlights
In a large cohort of patients with chronic hepatitis C infection, sustained virologic response after direct-acting antiviral therapy lowered, but did not eliminate, the risk of hepatocellular carcinoma
Direct-acting antiviral (DAA) therapy has revolutionized the treatment of chronic hepatitis C virus (HCV) infection
Feld), Kanwal et al report their retrospective analysis of a large Veterans’ Health Administration–based cohort of 22,500 HCV patients treated with DAAs
Summary
In a large cohort of patients with chronic hepatitis C infection, sustained virologic response after direct-acting antiviral therapy lowered, but did not eliminate, the risk of hepatocellular carcinoma. There was no difference in tumor stage or size among patients who developed HCC either during or after antiviral therapy, suggesting that direct acting-antivirals do not promote hepatocarcinogenesis These data support that DAAs reduce, but do not eliminate subsequent HCC risk for HCV patients. I n response to recent outbreaks of fatal multidrug-resistant organism infections attributed to contaminated duodenoscopes, a US Food and Drug Administration advisory panel deemed that current standards of duodenoscope reprocessing did not provide a reasonable level of safety and effectiveness. This finding has led experts to suggest several additional methods for reprocessing of duodenoscopes, including enhanced disinfection or sterilization.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
